Bruker (NASDAQ:BRKR) Stock Falls 6.5% – Here’s Why

Bruker Corporation (NASDAQ:BRKR)’s share price traded down 6.5% during mid-day trading on Tuesday. The stock traded as low as $59.59 and last traded at $59.7050. 430,729 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 2,351,235 shares. The stock had previously closed at $63.86.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BRKR. The Goldman Sachs Group upgraded Bruker from a “strong sell” rating to a “strong-buy” rating in a research report on Monday, September 21st. Barclays lifted their price target on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Leerink Partners increased their price objective on shares of Bruker from $60.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. TD Cowen restated a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Finally, Guggenheim upped their target price on shares of Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Bruker Stock Performance

The stock’s 50-day moving average price is $58.94 and its 200 day moving average price is $52.04. The firm has a market cap of $9.39 billion, a P/E ratio of -87.59, a price-to-earnings-growth ratio of 1.93 and a beta of 1.22. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. During the same quarter last year, the firm earned $0.32 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the sale, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Pallas Capital Advisors LLC bought a new stake in shares of Bruker in the 2nd quarter valued at about $570,746,000. Edmond DE Rothschild Holding S.A. acquired a new position in Bruker during the second quarter worth approximately $169,899,000. Sculptor Capital LP increased its position in Bruker by 9.0% during the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after buying an additional 270,000 shares during the last quarter. Franklin Resources Inc. raised its stake in Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in shares of Bruker by 86.2% in the second quarter. Alyeska Investment Group L.P. now owns 1,410,164 shares of the medical research company’s stock valued at $84,864,000 after buying an additional 653,007 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.